Ratings National Health Investors, Inc.

Equities

NHI

US63633D1046

Market Closed - Nyse 04:00:02 2024-05-31 pm EDT 5-day change 1st Jan Change
66.08 USD +1.30% Intraday chart for National Health Investors, Inc. +1.71% +18.32%

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • The company is one of the best yield companies with high dividend expectations.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • The opinion of analysts covering the stock has improved over the past four months.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

  • The company's earnings growth outlook lacks momentum and is a weakness.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • The company benefits from high valuations in earnings multiples.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Specialized REITs

1st Jan change Capi. Investor Rating ESG Refinitiv
+18.32% 2.87B
C-
+14.97% 61.99B
A-
+0.51% 14.01B
A
+5.45% 7.99B
B
-5.80% 6.14B
B-
+14.32% 3.63B
C-
+2.24% 3.38B
C+
+9.16% 3.22B
C
-6.13% 3.08B
B+
-14.85% 2.42B
A-
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. NHI Stock
  4. Ratings National Health Investors, Inc.